{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:37:38Z","timestamp":1792784258848,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Inflammatory Bowel Disease Innovative Research Funds at Houston Methodist Hospital"},{"name":"Josephine Hughes Sterling Foundation"},{"name":"Clinical Scholars Award at Houston Methodist Hospital"},{"name":"The Fondren Foundation","id":[{"id":"https:\/\/ror.org\/01xgwhs23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01329-4","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:24:24Z","timestamp":1757489064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD\u2019s Cardiometabolic Risks"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9842-8712","authenticated-orcid":false,"given":"Oscar","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-0159","authenticated-orcid":false,"given":"Dayoung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1753-4043","authenticated-orcid":false,"given":"Megan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-6885","authenticated-orcid":false,"given":"Christopher","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-2269","authenticated-orcid":false,"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-1224","authenticated-orcid":false,"given":"Bincy P.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"publisher","unstructured":"Lakhanpal S, Aggarwal K, Kaur H, et al. Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease. Intest Res. 2024;14. https:\/\/doi.org\/10.5217\/ir.2023.00104.","DOI":"10.5217\/ir.2023.00104"},{"issue":"4","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ajg.2011.63","volume":"106","author":"AJ Yarur","year":"2011","unstructured":"Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106(4):741\u20137. https:\/\/doi.org\/10.1038\/ajg.2011.63.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1389450116666150202161500","volume":"16","author":"S Rudolf","year":"2015","unstructured":"Rudolf S, Gunther M, Martin S. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets. 2015;16(3):181\u20138. https:\/\/doi.org\/10.2174\/1389450116666150202161500.","journal-title":"Curr Drug Targets"},{"issue":"11","key":"1329_CR4","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/ibd\/izy157","volume":"24","author":"NE Mitchell","year":"2018","unstructured":"Mitchell NE, Harrison N, Junga Z, Singla M. Heart under attack: cardiac manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(11):2322\u20136. https:\/\/doi.org\/10.1093\/ibd\/izy157.","journal-title":"Inflamm Bowel Dis"},{"key":"1329_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021526","author":"A Saez","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, Sanchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021526.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ibd\/izac199","volume":"29","author":"H Cao","year":"2023","unstructured":"Cao H, Diao J, Liu H, et al. The pathogenicity and synergistic action of Th1 and Th17 cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2023;29(5):818\u201329. https:\/\/doi.org\/10.1093\/ibd\/izac199.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/MIB.0000000000000121","volume":"20","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Diegelmann J, Beigel F, Brand S. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-alpha-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes. Inflamm Bowel Dis. 2014;20(9):1502\u201315. https:\/\/doi.org\/10.1097\/MIB.0000000000000121.","journal-title":"Inflamm Bowel Dis"},{"key":"1329_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00432","volume":"7","author":"Y Sun","year":"2019","unstructured":"Sun Y, Li L, Xie R, Wang B, Jiang K, Cao H. Stress triggers flare of inflammatory bowel disease in children and adults. Front Pediatr. 2019;7: 432. https:\/\/doi.org\/10.3389\/fped.2019.00432.","journal-title":"Front Pediatr"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"767456","DOI":"10.3389\/fimmu.2021.767456","volume":"12","author":"LW Kaminsky","year":"2021","unstructured":"Kaminsky LW, Al-Sadi R, Ma TY. IL-1beta and the intestinal epithelial tight junction barrier. Front Immunol. 2021;12:767456. https:\/\/doi.org\/10.3389\/fimmu.2021.767456.","journal-title":"Front Immunol"},{"issue":"6","key":"1329_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103331","volume":"22","author":"F Meyer","year":"2023","unstructured":"Meyer F, Wendling D, Demougeot C, Prati C, Verhoeven F. Cytokines and intestinal epithelial permeability: a systematic review. Autoimmun Rev. 2023;22(6): 103331. https:\/\/doi.org\/10.1016\/j.autrev.2023.103331.","journal-title":"Autoimmun Rev"},{"key":"1329_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.669913","volume":"8","author":"AE Jergens","year":"2021","unstructured":"Jergens AE, Parvinroo S, Kopper J, Wannemuehler MJ. Rules of engagement: epithelial-microbe interactions and inflammatory bowel disease. Front Med. 2021;8: 669913. https:\/\/doi.org\/10.3389\/fmed.2021.669913.","journal-title":"Front Med"},{"key":"1329_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2022.104458","volume":"146","author":"S Kul","year":"2023","unstructured":"Kul S, Caliskan Z, Guvenc TS, et al. Gut microbiota-derived metabolite trimethylamine N-oxide and biomarkers of inflammation are linked to endothelial and coronary microvascular function in patients with inflammatory bowel disease. Microvasc Res. 2023;146: 104458. https:\/\/doi.org\/10.1016\/j.mvr.2022.104458.","journal-title":"Microvasc Res"},{"issue":"1","key":"1329_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-020-00280-5","volume":"15","author":"L Petagna","year":"2020","unstructured":"Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn\u2019s disease inflammation and recurrence. Biol Direct. 2020;15(1): 23. https:\/\/doi.org\/10.1186\/s13062-020-00280-5.","journal-title":"Biol Direct"},{"key":"1329_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005892","author":"W Feng","year":"2017","unstructured":"Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.005892.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1329_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7759\/cureus.10544","volume":"12","author":"K Konduhhatla","year":"2020","unstructured":"Konduhhatla K, Kaushal A, Daoud A, Shabbir H, Mostafa JA. Pro-Atherogenic inflammatory mediators in inflammatory bowel disease patients increase the risk of thrombosis, coronary artery disease, and myocardial infarction: A scientific dilemma. Cureus J Med Sci. 2020;12(9):10. https:\/\/doi.org\/10.7759\/cureus.10544.","journal-title":"Cureus J Med Sci"},{"issue":"2","key":"1329_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056944","volume":"8","author":"SL Kristensen","year":"2013","unstructured":"Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2013a Danish nationwide cohort study. PLoS One. 2013;8(2): e56944. https:\/\/doi.org\/10.1371\/journal.pone.0056944.","journal-title":"PLoS One"},{"issue":"5","key":"1329_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCHEARTFAILURE.114.001152","volume":"7","author":"SL Kristensen","year":"2014","unstructured":"Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish nationwide cohort study. Circ Heart Fail. 2014;7(5):717\u201322. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001152.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrgastro.2014.202","volume":"12","author":"S Singh","year":"2015","unstructured":"Singh S, Kullo IJ, Pardi DS, Loftus EV Jr. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(1):26\u201335. https:\/\/doi.org\/10.1038\/nrgastro.2014.202.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1329_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00760-8","volume":"13","author":"Y Ma","year":"2025","unstructured":"Ma Y, Chen H, Lv W, et al. Global, regional and national burden of rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a systematic and comprehensive analysis of the global burden of disease study 2021. Biomark Res. 2025;13(1): 47. https:\/\/doi.org\/10.1186\/s40364-025-00760-8.","journal-title":"Biomark Res"},{"issue":"1","key":"1329_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04711-x","volume":"39","author":"D Lin","year":"2024","unstructured":"Lin D, Jin Y, Shao X, et al. Global, regional, and national burden of inflammatory bowel disease, 1990\u20132021: insights from the global burden of disease 2021. Int J Colorectal Dis. 2024;39(1): 139. https:\/\/doi.org\/10.1007\/s00384-024-04711-x.","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"1329_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","volume":"17","author":"M Pujades-Rodriguez","year":"2020","unstructured":"Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 2020;17(12): e1003432. https:\/\/doi.org\/10.1371\/journal.pmed.1003432.","journal-title":"PLoS Med"},{"issue":"3","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.tcm.2023.01.002","volume":"34","author":"H Kumarapperuma","year":"2024","unstructured":"Kumarapperuma H, Wang R, Little PJ, Kamato D. Mechanistic insight: linking cardiovascular complications of inflammatory bowel disease. Trends Cardiovasc Med. 2024;34(3):203\u201311. https:\/\/doi.org\/10.1016\/j.tcm.2023.01.002.","journal-title":"Trends Cardiovasc Med"},{"issue":"5","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4330\/wjc.v15.i5.217","volume":"15","author":"TG Grillo","year":"2023","unstructured":"Grillo TG, Silveira C, Quaglio AEV, et al. Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature. World J Cardiol. 2023;15(5):217\u201328. https:\/\/doi.org\/10.4330\/wjc.v15.i5.217.","journal-title":"World J Cardiol"},{"issue":"4","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"issue":"6","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/apt.17509","volume":"57","author":"PA Olivera","year":"2023","unstructured":"Olivera PA, Lasa JS, Peretto G, Zuily S, Danese S, Peyrin-Biroulet L. Review article: risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Aliment Pharmacol Ther. 2023;57(11):1231\u201348. https:\/\/doi.org\/10.1111\/apt.17509.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1329_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010190","volume":"13","author":"H Wu","year":"2025","unstructured":"Wu H, Xie T, Yu Q, et al. An analysis of the effectiveness and safety of Upadacitinib in the treatment of inflammatory bowel disease: a multicenter real-world study. Biomedicines. 2025;13(1): 190. https:\/\/doi.org\/10.3390\/biomedicines13010190.","journal-title":"Biomedicines"},{"key":"1329_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111229","volume":"126","author":"D-y Zheng","year":"2024","unstructured":"Zheng D-y, Wang Y-n, Huang Y-H, Jiang M, Dai C. Effectiveness and safety of Upadacitinib for inflammatory bowel disease: a systematic review and meta-analysis of RCT and real-world observational studies. Int Immunopharmacol. 2024;126: 111229. https:\/\/doi.org\/10.1016\/j.intimp.2023.111229.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1329_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/ibd\/izaa236","volume":"27","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Danese S, et al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies. Inflamm Bowel Dis. 2021;27(7):994\u20131007. https:\/\/doi.org\/10.1093\/ibd\/izaa236.","journal-title":"Inflamm Bowel Dis"},{"issue":"10340","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6.","journal-title":"Lancet"},{"issue":"26","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"1329_CR32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.033","author":"A Hart","year":"2025","unstructured":"Hart A, Panaccione R, Steinwurz F, et al. Efficacy and safety of Guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI study. Gastroenterology. 2025. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.033.","journal-title":"Gastroenterology"},{"issue":"9","key":"1329_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14740338.2023.2247976","volume":"22","author":"S Honap","year":"2023","unstructured":"Honap S, Netter P, Danese S, Peyrin-Biroulet L. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. Expert Opin Drug Saf. 2023;22(9):767\u201376. https:\/\/doi.org\/10.1080\/14740338.2023.2247976.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1329_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40168-020-00821-0","volume":"8","author":"N Kazemian","year":"2020","unstructured":"Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome. 2020;8(1):36. https:\/\/doi.org\/10.1186\/s40168-020-00821-0.","journal-title":"Microbiome"},{"issue":"1","key":"1329_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000993","volume":"6","author":"E Forkosh","year":"2019","unstructured":"Forkosh E, Ilan Y. The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy. Open Heart. 2019;6(1): e000993. https:\/\/doi.org\/10.1136\/openhrt-2018-000993.","journal-title":"Open Heart"},{"key":"1329_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8030126","author":"I Khan","year":"2019","unstructured":"Khan I, Ullah N, Zha L, et al. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence?? IBD treatment targeting the gut microbiome. Pathogens. 2019. https:\/\/doi.org\/10.3390\/pathogens8030126.","journal-title":"Pathogens"},{"issue":"7758","key":"1329_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655\u201362. https:\/\/doi.org\/10.1038\/s41586-019-1237-9.","journal-title":"Nature"},{"issue":"3","key":"1329_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/gutjnl-2020-321106","volume":"70","author":"AG Clooney","year":"2021","unstructured":"Clooney AG, Eckenberger J, Laserna-Mendieta E, et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021;70(3):499\u2013510. https:\/\/doi.org\/10.1136\/gutjnl-2020-321106.","journal-title":"Gut"},{"issue":"1","key":"1329_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49833-3","volume":"9","author":"MK Vester-Andersen","year":"2019","unstructured":"Vester-Andersen MK, Mirsepasi-Lauridsen HC, Prosberg MV, et al. Increased abundance of Proteobacteria in aggressive Crohn\u2019s disease seven years after diagnosis. Sci Rep. 2019;9(1): 13473. https:\/\/doi.org\/10.1038\/s41598-019-49833-3.","journal-title":"Sci Rep"},{"key":"1329_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00281","volume":"8","author":"M Lopez-Siles","year":"2018","unstructured":"Lopez-Siles M, Enrich-Capo N, Aldeguer X, et al. Alterations in the abundance and co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the colonic mucosa of inflammatory bowel disease subjects. Front Cell Infect Microbiol. 2018;8: 281. https:\/\/doi.org\/10.3389\/fcimb.2018.00281.","journal-title":"Front Cell Infect Microbiol"},{"key":"1329_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01166","volume":"8","author":"AM Patterson","year":"2017","unstructured":"Patterson AM, Mulder IE, Travis AJ, et al. Human gut symbiont Roseburia hominis promotes and regulates innate immunity. Front Immunol. 2017;8: 1166. https:\/\/doi.org\/10.3389\/fimmu.2017.01166.","journal-title":"Front Immunol"},{"issue":"3","key":"1329_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090981","volume":"9","author":"ES Wills","year":"2014","unstructured":"Wills ES, Jonkers DM, Savelkoul PH, Masclee AA, Pierik MJ, Penders J. Fecal microbial composition of ulcerative colitis and Crohn\u2019s disease patients in remission and subsequent exacerbation. PLoS One. 2014;9(3): e90981. https:\/\/doi.org\/10.1371\/journal.pone.0090981.","journal-title":"PLoS One"},{"issue":"1","key":"1329_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15342-5","volume":"11","author":"FJ Ryan","year":"2020","unstructured":"Ryan FJ, Ahern AM, Fitzgerald RS, et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun. 2020;11(1): 1512. https:\/\/doi.org\/10.1038\/s41467-020-15342-5.","journal-title":"Nat Commun"},{"issue":"1","key":"1329_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00900-1","volume":"8","author":"Z Jie","year":"2017","unstructured":"Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8(1): 845. https:\/\/doi.org\/10.1038\/s41467-017-00900-1.","journal-title":"Nat Commun"},{"issue":"1","key":"1329_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18756-2","volume":"8","author":"X Cui","year":"2018","unstructured":"Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep. 2018;8(1): 635. https:\/\/doi.org\/10.1038\/s41598-017-18756-2.","journal-title":"Sci Rep"},{"key":"1329_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2266","volume":"3","author":"FH Karlsson","year":"2012","unstructured":"Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3: 1245. https:\/\/doi.org\/10.1038\/ncomms2266.","journal-title":"Nat Commun"},{"issue":"10","key":"1329_CR47","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1152\/physiolgenomics.00070.2018","volume":"50","author":"Q Zhu","year":"2018","unstructured":"Zhu Q, Gao R, Zhang Y, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics. 2018;50(10):893\u2013903. https:\/\/doi.org\/10.1152\/physiolgenomics.00070.2018.","journal-title":"Physiol Genomics"},{"issue":"1","key":"1329_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01786-9","volume":"16","author":"G Matacchione","year":"2024","unstructured":"Matacchione G, Piacenza F, Pimpini L, Rosati Y, Marcozzi S. The role of the gut microbiota in the onset and progression of heart failure: insights into epigenetic mechanisms and aging. Clin Epigenetics. 2024;16(1): 175. https:\/\/doi.org\/10.1186\/s13148-024-01786-9.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1329_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ibd\/izz119","volume":"26","author":"E Ferrer-Picon","year":"2020","unstructured":"Ferrer-Picon E, Dotti I, Corraliza AM, et al. Intestinal inflammation modulates the epithelial response to butyrate in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(1):43\u201355. https:\/\/doi.org\/10.1093\/ibd\/izz119.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1329_CR50","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1053\/j.gastro.2017.08.028","volume":"153","author":"S Nikolaus","year":"2017","unstructured":"Nikolaus S, Schulte B, Al-Massad N, et al. Increased Tryptophan metabolism is associated with activity of inflammatory bowel diseases. Gastroenterology. 2017;153(6):1504\u2013e15161502. https:\/\/doi.org\/10.1053\/j.gastro.2017.08.028.","journal-title":"Gastroenterology"},{"issue":"2","key":"1329_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","volume":"4","author":"EA Franzosa","year":"2019","unstructured":"Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut Microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293\u2013305. https:\/\/doi.org\/10.1038\/s41564-018-0306-4.","journal-title":"Nat Microbiol"},{"issue":"4","key":"1329_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","volume":"62","author":"H Duboc","year":"2013","unstructured":"Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2012-302578.","journal-title":"Gut"},{"issue":"1","key":"1329_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41385-018-0087-3","volume":"12","author":"DC Macias-Ceja","year":"2019","unstructured":"Macias-Ceja DC, Ortiz-Masia D, Salvador P, et al. Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunol. 2019;12(1):178\u201387. https:\/\/doi.org\/10.1038\/s41385-018-0087-3.","journal-title":"Mucosal Immunol"},{"issue":"4","key":"1329_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223\u201337. https:\/\/doi.org\/10.1038\/s41575-019-0258-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"1329_CR55","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1161\/ATVBAHA.118.311023","volume":"38","author":"A Haghikia","year":"2018","unstructured":"Haghikia A, Li XS, Liman TG, et al. Gut microbiota-dependent trimethylamine n-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. Arterioscler Thromb Vasc Biol. 2018;38(9):2225\u201335. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311023.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"1329_CR56","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1681\/ASN.2015121302","volume":"27","author":"R Poesen","year":"2016","unstructured":"Poesen R, Claes K, Evenepoel P, et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J Am Soc Nephrol. 2016;27(11):3479\u201387. https:\/\/doi.org\/10.1681\/ASN.2015121302.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1329_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4330\/wjc.v12.i4.110","volume":"12","author":"M Novakovic","year":"2020","unstructured":"Novakovic M, Rout A, Kingsley T, et al. Role of gut microbiota in cardiovascular diseases. World J Cardiol. 2020;12(4):110\u201322. https:\/\/doi.org\/10.4330\/wjc.v12.i4.110.","journal-title":"World J Cardiol"},{"issue":"8","key":"1329_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/nu9080859","volume":"9","author":"K Lau","year":"2017","unstructured":"Lau K, Srivatsav V, Rizwan A, et al. Bridging the gap between gut microbial dysbiosis and cardiovascular diseases. Nutrients. 2017;9(8): 859. https:\/\/doi.org\/10.3390\/nu9080859.","journal-title":"Nutrients"},{"issue":"1","key":"1329_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","volume":"36","author":"T Cederholm","year":"2017","unstructured":"Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49\u201364. https:\/\/doi.org\/10.1016\/j.clnu.2016.09.004.","journal-title":"Clin Nutr"},{"issue":"3","key":"1329_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1365-2036.2003.01482.x","volume":"17","author":"J Goh","year":"2003","unstructured":"Goh J, O\u2019Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(3):307\u201320. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01482.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1329_CR61","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/MCO.0000000000000226","volume":"18","author":"R Weisshof","year":"2015","unstructured":"Weisshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2015;18(6):576\u201381. https:\/\/doi.org\/10.1097\/MCO.0000000000000226.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"10","key":"1329_CR62","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ibd.22906","volume":"18","author":"C Hwang","year":"2012","unstructured":"Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis. 2012;18(10):1961\u201381. https:\/\/doi.org\/10.1002\/ibd.22906.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"1329_CR63","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.mayocp.2022.06.008","volume":"97","author":"M Delgado-Velandia","year":"2022","unstructured":"Delgado-Velandia M, Maroto-Rodr\u00edguez J, Ortol\u00e1 R, Garc\u00eda-Esquinas E, Rodr\u00edguez-Artalejo F, Sotos-Prieto M. Plant-Based diets and All-cause and cardiovascular mortality in a nationwide cohort in spain: the ENRICA study. Mayo Clin Proc. 2022;97(11):2005\u201315. https:\/\/doi.org\/10.1016\/j.mayocp.2022.06.008.","journal-title":"Mayo Clin Proc"},{"key":"1329_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1010737","volume":"9","author":"S Rehman","year":"2022","unstructured":"Rehman S, Jianglin Z. Micronutrient deficiencies and cardiac health. Front Nutr. 2022;9: 1010737. https:\/\/doi.org\/10.3389\/fnut.2022.1010737.","journal-title":"Front Nutr"},{"issue":"3","key":"1329_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.amjmed.2014.10.014","volume":"128","author":"RJ Widmer","year":"2015","unstructured":"Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015;128(3):229\u201338. https:\/\/doi.org\/10.1016\/j.amjmed.2014.10.014.","journal-title":"Am J Med"},{"issue":"5","key":"1329_CR66","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3945\/ajcn.2010.29673","volume":"92","author":"F Sofi","year":"2010","unstructured":"Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189\u201396. https:\/\/doi.org\/10.3945\/ajcn.2010.29673.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"1329_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izaa097","volume":"27","author":"F Chicco","year":"2021","unstructured":"Chicco F, Magri S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1\u20139. https:\/\/doi.org\/10.1093\/ibd\/izaa097.","journal-title":"Inflamm Bowel Dis"},{"key":"1329_CR68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fmed.2014.00058","volume":"1","author":"G Rogler","year":"2014","unstructured":"Rogler G, Vavricka S. Anemia in inflammatory bowel disease: an under-estimated problem? Front Med (Lausanne). 2014;1:58. https:\/\/doi.org\/10.3389\/fmed.2014.00058.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"1329_CR69","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/j.crohns.2012.10.013","volume":"7","author":"RJ Basseri","year":"2013","unstructured":"Basseri RJ, Nemeth E, Vassilaki ME, et al. Hepcidin is a key mediator of anemia of inflammation in crohn\u2019s disease. J Crohns Colitis. 2013;7(8):e286\u2013291. https:\/\/doi.org\/10.1016\/j.crohns.2012.10.013.","journal-title":"J Crohns Colitis"},{"issue":"13","key":"1329_CR70","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3748\/wjg.v20.i13.3542","volume":"20","author":"D Guagnozzi","year":"2014","unstructured":"Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol. 2014;20(13):3542\u201351. https:\/\/doi.org\/10.3748\/wjg.v20.i13.3542.","journal-title":"World J Gastroenterol"},{"key":"1329_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.1021","author":"L Soulat-Dufour","year":"2024","unstructured":"Soulat-Dufour L, Djebnoune H, Lang S, et al. Anemia and 4 cavities myocardial strain in acute heart failure. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.1021.","journal-title":"Eur Heart J"},{"issue":"3","key":"1329_CR72","first-page":"340","volume":"33","author":"N Hegde","year":"2006","unstructured":"Hegde N, Rich MW, Gayomali C. The cardiomyopathy of iron deficiency. Tex Heart Inst J. 2006;33(3):340\u20134.","journal-title":"Tex Heart Inst J"},{"key":"1329_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2015.03.159","volume":"186","author":"G Kaiafa","year":"2015","unstructured":"Kaiafa G, Kanellos I, Savopoulos C, Kakaletsis N, Giannakoulas G, Hatzitolios AI. Is anemia a new cardiovascular risk factor? Int J Cardiol. 2015;186:117\u201324. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.159.","journal-title":"Int J Cardiol"},{"key":"1329_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020656","author":"A Dhaliwal","year":"2021","unstructured":"Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in inflammatory bowel disease: a narrative overview. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13020656.","journal-title":"Nutrients"},{"issue":"1","key":"1329_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/ibd\/izy212","volume":"25","author":"E Ryan","year":"2019","unstructured":"Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2019;25(1):67\u201373. https:\/\/doi.org\/10.1093\/ibd\/izy212.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1329_CR76","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21037\/atm-22-1126","volume":"10","author":"S Liu","year":"2022","unstructured":"Liu S, Ding X, Maggiore G, et al. Sarcopenia is associated with poor clinical outcomes in patients with inflammatory bowel disease: a prospective cohort study. Ann Transl Med. 2022;10(6):367. https:\/\/doi.org\/10.21037\/atm-22-1126.","journal-title":"Ann Transl Med"},{"issue":"20","key":"1329_CR77","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","volume":"147","author":"AA Damluji","year":"2023","unstructured":"Damluji AA, Alfaraidhy M, AlHajri N, et al. Sarcopenia and cardiovascular diseases. Circulation. 2023;147(20):1534\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064071.","journal-title":"Circulation"},{"issue":"7","key":"1329_CR78","doi-asserted-by":"publisher","first-page":"615","DOI":"10.11909\/j.issn.1671-5411.2016.07.004","volume":"13","author":"A Collamati","year":"2016","unstructured":"Collamati A, Marzetti E, Calvani R, et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol. 2016;13(7):615\u201324. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.07.004.","journal-title":"J Geriatr Cardiol"},{"key":"1329_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101264","volume":"44","author":"K Gao","year":"2022","unstructured":"Gao K, Cao LF, Ma WZ, et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: findings from the China health and retirement longitudinal study. EClinicalMedicine. 2022;44: 101264. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101264.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"1329_CR80","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jcsm.13221","volume":"14","author":"X Zuo","year":"2023","unstructured":"Zuo X, Li X, Tang K, et al. Sarcopenia and cardiovascular diseases: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1183\u201398. https:\/\/doi.org\/10.1002\/jcsm.13221.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1329_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.743710","volume":"8","author":"N He","year":"2021","unstructured":"He N, Zhang Y, Zhang L, Zhang S, Ye H. Relationship between sarcopenia and cardiovascular diseases in the elderly: an overview. Front Cardiovasc Med. 2021;8: 743710. https:\/\/doi.org\/10.3389\/fcvm.2021.743710.","journal-title":"Front Cardiovasc Med"},{"key":"1329_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/nu11051019","author":"J Fletcher","year":"2019","unstructured":"Fletcher J, Cooper SC, Ghosh S, Hewison M. The role of vitamin D in inflammatory bowel disease: mechanism to management. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11051019.","journal-title":"Nutrients"},{"issue":"23","key":"1329_CR83","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/eurheartj\/ehad165","volume":"44","author":"F Carbone","year":"2023","unstructured":"Carbone F, Liberale L, Libby P, Montecucco F. Vitamin D in atherosclerosis and cardiovascular events. Eur Heart J. 2023;44(23):2078\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehad165.","journal-title":"Eur Heart J"},{"issue":"4","key":"1329_CR84","doi-asserted-by":"publisher","first-page":"e00594","DOI":"10.34172\/jrhs.2023.129","volume":"23","author":"MA Rasouli","year":"2023","unstructured":"Rasouli MA, Darvishzadehdaledari S, Alizadeh Z, Moradi G, Gholami F, Mahmoudian A. Vitamin D supplementation and cardiovascular disease risks in more than 134000 individuals in 29 randomized clinical trials and 157000 individuals in 30 prospective cohort studies: an updated systematic review and meta-analysis. J Res Health Sci. 2023;23(4):e00594. https:\/\/doi.org\/10.34172\/jrhs.2023.129.","journal-title":"J Res Health Sci"},{"issue":"11","key":"1329_CR85","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4330\/wjc.v15.i11.553","volume":"15","author":"A Bhardwaj","year":"2023","unstructured":"Bhardwaj A, Singh A, Midha V, et al. Cardiovascular implications of inflammatory bowel disease: an updated review. World J Cardiol. 2023;15(11):553\u201370. https:\/\/doi.org\/10.4330\/wjc.v15.i11.553.","journal-title":"World J Cardiol"},{"issue":"10","key":"1329_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004305","volume":"20","author":"J Sun","year":"2023","unstructured":"Sun J, Roelstraete B, Svennberg E, et al. Long-term risk of arrhythmias in patients with inflammatory bowel disease: a population-based, sibling-controlled cohort study. PLoS Med. 2023;20(10): e1004305. https:\/\/doi.org\/10.1371\/journal.pmed.1004305.","journal-title":"PLoS Med"},{"issue":"22","key":"1329_CR87","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3748\/wjg.v25.i22.2788","volume":"25","author":"YJ Choi","year":"2019","unstructured":"Choi YJ, Choi EK, Han KD, et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: a nationwide population-based study. World J Gastroenterol. 2019;25(22):2788\u201398. https:\/\/doi.org\/10.3748\/wjg.v25.i22.2788.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1329_CR88","doi-asserted-by":"publisher","first-page":"S542","DOI":"10.1016\/S0016-5085(24)01719-0","volume":"166","author":"CN Bernstein","year":"2024","unstructured":"Bernstein CN, Nugent Z, Narous M, Kirshenbaum L, Rabinovich-Nikitin I. Risk of arrhythmia in inflammatory bowel disease: a historical population-based cohort study. Gastroenterology. 2024;166(5):S542-542.","journal-title":"Gastroenterology"},{"issue":"4","key":"1329_CR89","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/europace\/eut312","volume":"16","author":"SL Kristensen","year":"2014","unstructured":"Kristensen SL, Lindhardsen J, Ahlehoff O, et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. Europace. 2014;16(4):477\u201384. https:\/\/doi.org\/10.1093\/europace\/eut312.","journal-title":"Europace"},{"issue":"3","key":"1329_CR90","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2005.06.021.","journal-title":"Gastroenterology"},{"issue":"3","key":"1329_CR91","doi-asserted-by":"publisher","first-page":"e14010","DOI":"10.7759\/cureus.14010","volume":"13","author":"RS Patel","year":"2021","unstructured":"Patel RS, Rohit Reddy S, Llukmani A, et al. Cardiovascular manifestations in inflammatory bowel disease: a systematic review of the pathogenesis and management of pericarditis. Cureus. 2021;13(3):e14010. https:\/\/doi.org\/10.7759\/cureus.14010.","journal-title":"Cureus"},{"key":"1329_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(24)03736-7","author":"T Shah","year":"2024","unstructured":"Shah T, Shah J, Shah K, Weber B, Garshick MS. Inflammatory bowel disease is associated with pericarditis: a cross-sectional study in an NIH-sponsored, nationwide database. J Am Coll Cardiol. 2024. https:\/\/doi.org\/10.1016\/s0735-1097(24)03736-7.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1329_CR93","doi-asserted-by":"publisher","first-page":"e4248","DOI":"10.7759\/cureus.4248","volume":"11","author":"M Kumar","year":"2019","unstructured":"Kumar M, Tandon V, Mosebach CM, Lopetegui Lia N, Miller W. Acute myopericarditis with crohn\u2019s disease Flare-up. Cureus. 2019;11(3):e4248. https:\/\/doi.org\/10.7759\/cureus.4248.","journal-title":"Cureus"},{"issue":"5","key":"1329_CR94","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","volume":"13","author":"CRH Hedin","year":"2019","unstructured":"Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy191.","journal-title":"J Crohns Colitis"},{"issue":"28","key":"1329_CR95","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehae338","volume":"45","author":"J Sun","year":"2024","unstructured":"Sun J, Yao J, Olen O, et al. Risk of heart failure in inflammatory bowel disease: a Swedish population-based study. Eur Heart J. 2024;45(28):2493\u2013504. https:\/\/doi.org\/10.1093\/eurheartj\/ehae338.","journal-title":"Eur Heart J"},{"issue":"28","key":"1329_CR96","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/eurheartj\/ehae339","volume":"45","author":"MJ Feinstein","year":"2024","unstructured":"Feinstein MJ. Human immunology of heart failure: deconstructing inflammatory risk. Eur Heart J. 2024;45(28):2505\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehae339.","journal-title":"Eur Heart J"},{"issue":"12","key":"1329_CR97","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","volume":"26","author":"K Cheng","year":"2020","unstructured":"Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26(12):1231\u201341. https:\/\/doi.org\/10.3748\/wjg.v26.i12.1231.","journal-title":"World J Gastroenterol"},{"issue":"38","key":"1329_CR98","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017309","volume":"98","author":"YH Kim","year":"2019","unstructured":"Kim YH, Pfaller B, Marson A, Yim HW, Huang V, Ito S. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(38): e17309. https:\/\/doi.org\/10.1097\/MD.0000000000017309.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1329_CR99","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/jth.13638","volume":"15","author":"AT Hansen","year":"2017","unstructured":"Hansen AT, Erichsen R, Horvath-Puho E, Sorensen HT. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J Thromb Haemost. 2017;15(4):702\u20138. https:\/\/doi.org\/10.1111\/jth.13638.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1329_CR100","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1572-0241.2003.04026.x","volume":"99","author":"CA Solem","year":"2004","unstructured":"Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99(1):97\u2013101. https:\/\/doi.org\/10.1046\/j.1572-0241.2003.04026.x.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1329_CR101","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/ibd\/izy058","volume":"24","author":"MT Weng","year":"2018","unstructured":"Weng MT, Park SH, Matsuoka K, et al. Incidence and risk factor analysis of thromboembolic events in East Asian patients with inflammatory bowel disease, a multinational collaborative study. Inflamm Bowel Dis. 2018;24(8):1791\u2013800. https:\/\/doi.org\/10.1093\/ibd\/izy058.","journal-title":"Inflamm Bowel Dis"},{"key":"1329_CR102","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1093\/ecco-jcc\/jjy222.320","volume":"13","author":"TJ Kim","year":"2019","unstructured":"Kim TJ, Kong SM, Shin JB, et al. P196 Risk of venous thromboembolism according to disease activity, hospitalisation, or surgry in inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis. 2019;13:S189\u201390. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy222.320.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"1329_CR103","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/codi.14853","volume":"22","author":"T McKechnie","year":"2020","unstructured":"McKechnie T, Wang J, Springer JE, Gross PL, Forbes S, Eskicioglu C. Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: a comprehensive systematic clinical review. Colorectal Dis. 2020;22(6):663\u201378. https:\/\/doi.org\/10.1111\/codi.14853.","journal-title":"Colorectal Dis"},{"issue":"6","key":"1329_CR104","first-page":"294","volume":"18","author":"O Baser","year":"2012","unstructured":"Baser O, Sengupta N, Dysinger A, Wang L. Thromboembolism prophylaxis in medical inpatients: effect on outcomes and costs. Am J Manag Care. 2012;18(6):294\u2013302.","journal-title":"Am J Manag Care"},{"issue":"11","key":"1329_CR105","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.cgh.2014.02.034","volume":"12","author":"AN Ananthakrishnan","year":"2014","unstructured":"Ananthakrishnan AN, Cagan A, Gainer VS, et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(11):1905\u201310. https:\/\/doi.org\/10.1016\/j.cgh.2014.02.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1329_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010251","author":"G Dhaliwal","year":"2023","unstructured":"Dhaliwal G, Patrone MV, Bickston SJ. Venous thromboembolism in patients with inflammatory bowel disease. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm13010251.","journal-title":"J Clin Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01329-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:24:27Z","timestamp":1757489067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01329-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01329-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal subjects were used in this study. All studies with human subjects are published and follow ethical, institutional standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"BPA is a consultant for Abbvie, Johnson and Johnson, Pfizer, Takeda, Celltrion, Lilly, Sanofi and on the Speaker\u2019s Bureau for Abbvie, Johnson and Johnson, Pfizer, Takeda, Lilly. KN serves as editor for the Evidence-Based Medicine, Clinical Trials, and Their Interpretations section. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"89"}}